GlassScriptPhysician profile
Janice Tran
NPI 1487692919
$10,019.37
in general payments reported to CMS, 2019-2025
44 companies · $2,676 in 2025
The $2,676 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,502 · 2022: $166 · 2023: $720 · 2024: $1,956 · 2025: $2,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191 · Long Term Medical Supply Or Device Loan: $2,147 · Education: $13.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.51 |
| Long Term Medical Supply Or Device Loan | $2,147.25 |
| Education | $13.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,259.92 | 2024-2025 | |
| Lilly USA, LLC | $2,051.98 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $2,045.49 | 2021-2025 | |
| Eli Lilly and Company | $500.00 | 2021 | |
| Abbvie INC. | $342.99 | 2022-2025 | |
| Pfizer INC. | $237.97 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $187.02 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $175.86 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Puma Biotechnology, INC. | $171.54 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.79 | 2023-2025 | |
| Genentech, INC. | $145.75 | 2024 | |
| Aveo Pharmaceuticals, INC. | $132.99 | 2025 | |
| Immunogen, INC. | $129.32 | 2023 | Elahere |
| Karyopharm Therapeutics INC. | $115.63 | 2023 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $96.05 | 2024-2025 | Enhertu, Tagrisso |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $91.31 | 2024-2025 | Ojjaara, Blenrep |
| Incyte Corporation | $89.96 | 2023-2025 | Monjuvi, Jakafi |
| Tactile Systems Technology INC | $89.31 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Gilead Sciences, INC. | $85.73 | 2023-2025 | Trodelvy |
| Emd Serono, INC. | $82.76 | 2023-2025 | Bavencio, Tepmetko |
| Tersera Therapeutics LLC | $61.37 | 2024-2025 | Zoladex |
| Daiichi Sankyo INC. | $57.94 | 2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $57.62 | 2023-2025 | |
| Stemline Therapeutics INC. | $55.55 | 2025 | Orserdu |
| Sobi, INC | $54.60 | 2025 | |
| Boston Scientific Corporation | $54.48 | 2023 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Rigel Pharmaceuticals, INC. | $51.51 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Beigene USA, INC. | $46.41 | 2023-2024 | Brukinsa |
| Blueprint Medicines Corporation | $41.61 | 2025 | Ayvakit |
| Taiho Oncology, INC. | $40.71 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $38.10 | 2025 | Opdivo, Opdualag |
| Adc Therapeutics America, INC. | $26.05 | 2024 | |
| Beone Medicines USA, INC. | $25.21 | 2025 | Brukinsa |
| Astellas Pharma US INC | $24.58 | 2024 | Padcev |
| Tempus Ai, INC | $24.29 | 2025 | Xt Cdx |
| Iovance Biotherapeutics, INC. | $23.99 | 2025 | Amtagvi |
| Takeda Pharmaceuticals U.S.A., INC. | $22.58 | 2025 | Iclusig |
| Springworks Therapeutics, INC. | $21.32 | 2024 | Ogsiveo |
| Servier Pharmaceuticals LLC | $19.46 | 2024 | |
| Genentech USA, INC. | $19.32 | 2025 | Itovebi |
| Morphosys, US INC. | $19.00 | 2023 | Monjuvi |
| Seagen INC. | $18.70 | 2023 | Padcev |
| Pharmacosmos Therapeutics INC. | $18.37 | 2023 | Monoferric |
| Recordati_rare_diseases_inc. | $18.23 | 2025 | Enjaymo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.